Simplify Logo

Full-Time

Medical Science Liaison/Senior Medical Science Liaison

Sleep Medicine, Southeast Region

Posted on 6/18/2024

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Develops therapies for CNS disorders

Hardware
Biotechnology

Compensation Overview

$150k - $200kAnnually

+ Bonus + Equity

Senior

Florida, USA + 4 more

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Advanced degree: MD, PharmD, or PhD required
  • Preference for candidates with previous industry experience
  • Preference for candidates with neurology, neuroscience, psychiatry and/or sleep therapeutic experience
  • Candidate must reside within the geographic area
  • Ability to travel up to 75%, including overnight stays and weekend, as needed
  • Meet requirements for health industry representative credentialing to gain access to healthcare facilities within the territory
Responsibilities
  • Systematically identify and develop relationships with healthcare professionals (HCPs)
  • Provide fair and balanced scientific information to HCPs and internal business partners
  • Lead scientific discovery and communicate insights from discussions with HCPs
  • Identify, analyze, and translate specific needs within the territory
  • Collaborate with internal partners to advance clinical and business objectives
  • Build and maintain technical and clinical expertise in major depressive disorder and other neuroscience therapeutic areas
  • Maintain knowledge of global and regional market issues and product knowledge
  • Contribute to the growth of the National Sleep Field Medical Team
  • Execute key job functions including documentation of field activities and submission of medical insights
  • Provide high-level support for company-sponsored trials and investigator-initiated research proposals
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

92%

1 year growth

92%

2 year growth

92%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.
INACTIVE